{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.0","upperLimit":"32.2","value":"17.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"}],"units":"Participants"}],"description":"TRM is defined as death not directly due to disease","dispersionType":"95% Confidence Interval","groups":[{"description":"All participants will receive a conditioning regimen of Fludarabine, Melphalan and Total Body Irradiation prior to transplantation of HLA-Haploidentical Related Hematopoietic Cells (Haplo-HCT)\n\nFludarabine: Fludarabine 30mg/m\\^2/day will be administered over 30-60 minutes intravenous infusion on Days -6 through -2 for a total dose of 150 mg/m\\^2\n\nMelphalan: Melphalan 70 mg/m\\^2 over 45 minutes will be administered Day -6. Melphalan dose will be calculated based on Actual Body Weight.\n\nTotal Body Irradiation: Total Body Irradiation (TBI) will be delivered at a dose of 200 centigray units (cGy)","id":"OG000","title":"Conditioning Regimen + Transplant"}],"paramType":"NUMBER","populationDescription":"Evaluable Participants","reportingStatus":"POSTED","timeFrame":"at 6 months post-transplant","title":"Percentage of Participants With Treatment Related Mortality (TRM) at 6 Months","type":"SECONDARY","unitOfMeasure":"percentage of participants"}